Verastem, Inc. (VSTM) Spending and interest coverage
- R&D / revenue · 12 months: Value 160.20%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 11.06%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -108.19×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 160.20% | Research and development expense / revenue. Period ending 2026-06-30. $140.22M ÷ $87.53M × 100 ≈ 160.20% |
| Stock-based compensation / revenue · 12 months | 11.06% | Share-based compensation / revenue. Period ending 2026-06-30. $9.68M ÷ $87.53M × 100 ≈ 11.06% |
| Interest coverage · 12 months | -108.19× | Operating income ÷ reported interest expense. $-159.80M ÷ $1.48M ≈ -108.19× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 140.22M USD | Research and Development Expense |
| Revenue | 87.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.68M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -159.80M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 1.48M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $140.22M | $87.53M | $9.68M | $-159.80M | $1.48M | 160.20% | 11.06% | -108.19× | Reported |
| 2026-03-31 | $123.67M | $49.59M | $9.66M | $-170.85M | $1.33M | 249.40% | 19.49% | -128.65× | Reported |
| 2025-12-31 | $114.60M | $30.91M | $9.40M | $-170.13M | $1.14M | 370.70% | 30.42% | -149.50× | Reported |
| 2025-09-30 | $103.74M | $13.38M | $9.40M | $-160.24M | $1.87M | 775.36% | 70.24% | -85.74× | Reported |
| 2025-06-30 | $99.50M | $2.14M | $9.15M | $-156.56M | $2.70M | 4656.20% | 428.40% | -58.03× | Reported |
| 2025-03-31 | $92.78M | (m) | $7.65M | $-131.07M | $3.62M | (m) | (m) | -36.17× | Reported |
| 2024-12-31 | $81.33M | $10.00M | $7.34M | $-114.96M | $4.56M | 813.34% | 73.42% | -25.20× | Reported |
| 2024-09-30 | $83.03M | (m) | $6.92M | $-114.50M | $4.54M | (m) | (m) | -25.24× | Reported |
| 2024-06-30 | $72.22M | (m) | $6.50M | $-98.78M | $4.52M | (m) | (m) | -21.87× | Reported |
| 2024-03-31 | $67.05M | (m) | $6.03M | $-100.80M | $4.50M | (m) | (m) | -22.40× | Reported |
| 2023-12-31 | $61.36M | (m) | $5.86M | $-92.08M | $4.14M | (m) | (m) | -22.25× | Reported |
| 2023-09-30 | $49.59M | (m) | $5.55M | $-77.79M | $3.74M | (m) | (m) | -20.78× | Reported |
| 2023-06-30 | $46.94M | (m) | $5.39M | $-74.19M | $3.33M | (m) | (m) | -22.27× | Reported |
| 2023-03-31 | $48.93M | (m) | $5.71M | $-75.30M | $2.85M | (m) | (m) | -26.42× | Reported |
| 2022-12-31 | $50.56M | $2.60M | $6.05M | $-72.94M | $2.14M | 1947.53% | 232.94% | -34.13× | Reported |
| 2022-09-30 | $51.21M | $3.14M | $6.33M | $-72.60M | $1.42M | 1630.50% | 201.66% | -51.02× | Reported |
| 2022-06-30 | $49.25M | $3.14M | $6.96M | $-69.74M | $8.69M | 1567.01% | 221.60% | -8.03× | Reported |
| 2022-03-31 | $44.09M | $3.64M | $7.38M | $-64.28M | $9.05M | 1210.35% | 202.50% | -7.10× | Reported |
| 2021-12-31 | $39.35M | $2.05M | $7.71M | $-61.41M | $9.97M | 1916.56% | 375.60% | -6.16× | Reported |
| 2021-09-30 | $38.10M | $2.01M | $9.07M | $-61.65M | $11.32M | 1891.96% | 450.35% | -5.45× | Reported |
| 2021-06-30 | $39.73M | $80.66M | $9.24M | $-31.79M | $5.23M | 49.26% | 11.45% | -6.07× | Reported |
| 2021-03-31 | $39.35M | $84.47M | $8.73M | $-37.11M | $6.09M | 46.58% | 10.33% | -6.09× | Reported |
| 2020-12-31 | $41.38M | $88.52M | $8.12M | $-49.36M | $15.79M | 46.74% | 9.17% | -3.13× | Reported |
| 2020-09-30 | $43.68M | $91.63M | $6.50M | $-65.90M | $19.89M | 47.67% | 7.09% | -3.31× | Reported |
| 2020-06-30 | $44.94M | $22.01M | $6.25M | $-107.02M | $23.04M | 204.17% | 28.42% | -4.65× | Reported |
| 2020-03-31 | $46.94M | $20.84M | $7.66M | $-124.03M | $26.35M | 225.25% | 36.76% | -4.71× | Reported |
| 2019-12-31 | $45.78M | $17.46M | $8.54M | $-132.34M | $20.61M | 262.25% | 48.92% | -6.42× | Reported |
| 2019-09-30 | $42.08M | $15.05M | $8.99M | $-133.31M | $19.11M | 279.63% | 59.74% | -6.98× | Reported |
| 2019-06-30 | $41.44M | $21.52M | $9.12M | $-128.77M | $14.93M | 192.50% | 42.36% | -8.63× | Reported |
| 2019-03-31 | $42.47M | $28.39M | $7.59M | $-108.69M | $10.26M | 149.61% | 26.74% | -10.59× | Reported |
| 2018-12-31 | $43.65M | $26.72M | $6.67M | $-94.78M | $5.81M | 163.37% | 24.97% | -16.31× | Reported |
| 2018-09-30 | $46.14M | (m) | $5.87M | $-78.58M | $2.19M | (m) | (m) | -35.95× | Reported |
| 2018-06-30 | $52.31M | (m) | $5.49M | $-80.14M | $1.43M | (m) | (m) | -55.89× | Reported |
| 2018-03-31 | $48.97M | (m) | $5.16M | $-75.42M | $1.03M | (m) | (m) | -73.43× | Reported |
| 2017-12-31 | $46.42M | (m) | $5.03M | $-67.80M | $559.00K | (m) | (m) | -121.30× | Reported |
| 2017-09-30 | $42.06M | (m) | $5.62M | $-61.55M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $28.54M | (m) | $5.26M | $-46.47M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $23.98M | (m) | $5.78M | $-41.72M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $19.78M | (m) | $6.29M | $-37.00M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $20.57M | (m) | $6.78M | $-37.16M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $27.66M | (m) | $7.85M | $-44.64M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $34.22M | (m) | $8.66M | $-51.39M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $40.56M | (m) | $10.09M | $-58.20M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $42.56M | (m) | $10.33M | $-60.24M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $40.30M | (m) | $11.12M | $-58.09M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $37.56M | (m) | $11.51M | $-55.72M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $35.45M | (m) | $12.36M | $-53.61M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $33.56M | (m) | $11.77M | $-51.00M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $31.30M | (m) | $11.40M | $-48.26M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $29.05M | (m) | $11.17M | $-45.45M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $25.93M | (m) | $9.68M | $-41.40M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $22.22M | (m) | $10.75M | $-37.98M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $23.57M | (m) | $9.57M | $-37.77M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $22.20M | (m) | $8.36M | $-34.38M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $21.71M | (m) | $7.40M | $-32.23M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $9.88M | (m) | $1.64M | $-13.70M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |